Physician profile
Mark Christopher Sievert
NPI 1720321912
$1,481.51
in general payments reported to CMS, 2019-2025
23 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $146 · 2021: $209 · 2022: $168 · 2023: $482 · 2024: $241 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $226.15 | 2020-2024 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $165.48 | 2022-2025 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $151.63 | 2022-2024 | |
| Amgen INC. | $132.66 | 2020-2025 | Krystexxa, Aranesp, Parsabiv |
| Fresenius USA Marketing, INC. | $131.55 | 2019-2024 | |
| Vifor Pharma, INC. | $89.30 | 2019-2023 | Veltassa |
| Horizon Therapeutics Plc | $83.84 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $80.44 | 2023 | Lupkynis |
| Travere Therapeutics, INC. | $62.36 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $60.29 | 2019-2023 | Jynarque |
| Tactile Systems Technology INC | $46.63 | 2021-2025 | Flexitouch Plus, Nimbl |
| Opko Pharmaceuticals, LLC | $34.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $33.84 | 2024 | |
| Renalytix Ai, INC. | $24.13 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Abbott Laboratories | $24.13 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $23.42 | 2023 | Evkeeza |
| Calliditas Therapeutics US INC. | $19.74 | 2024 | |
| Apellis Pharmaceuticals, INC. | $18.81 | 2025 | |
| Akebia Therapeutics INC | $18.28 | 2019-2020 | |
| Pfizer INC. | $17.58 | 2024 | |
| Kyowa Kirin, INC. | $17.57 | 2023 | |
| Janssen Pharmaceuticals, INC | $11.81 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $7.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sievert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.